Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;23(1):74-84.
doi: 10.18553/jmcp.2017.23.1.74.

Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study

Andrea Salazar-Ospina  1 , Pedro Amariles  1 , Jaime A Hincapié-García  1 , Sebastián González-Avendaño  2 , Dora M Benjumea  3 , Maria José Faus  4 , Luis F Rodriguez  5
Affiliations

Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study

Andrea Salazar-Ospina et al. J Manag Care Spec Pharm. 2017 Jan.

Abstract

Background: Bipolar I disorder (BD-I) is a chronic illness characterized by relapses alternating with periods of remission. Pharmacists can contribute to improved health outcomes in these patients through pharmaceutical care in association with a multidisciplinary health team; however, more evidence derived from randomized controlled trials (RCTs) is needed to demonstrate the effect of pharmaceutical care on patients with BD-I.

Objective: To assess the effectiveness of a pharmaceutical intervention using the Dader Method on patients with BD-I, measured by the decrease in the number of hospitalizations, emergency service consultations, and unscheduled outpatient visits from baseline through 1 year of follow-up.

Methods: This study is based on the EMDADER-TAB trial, which was an RCT designed to compare pharmaceutical care with the usual care given to outpatients with BD-I in a psychiatric clinic. The main outcome was the use of health care services, using Kaplan-Meier methods and Cox regression. The trial protocol was registered in ClinicalTrials.gov (Identifier NCT01750255).

Results: 92 patients were included in the EMDADER-TAB study: 43 pharmaceutical care patients (intervention group) and 49 usual care patients (control group). At baseline, no significant differences in demographic and clinical characteristics were found across the 2 groups. After 1 year of follow-up, the risk of hospitalizations and emergencies was higher for the control group than for the intervention group (HR = 9.03, P = 0.042; HR = 3.38, P = 0.034, respectively); however, the risk of unscheduled outpatient visits was higher for the intervention group (HR = 4.18, P = 0.028). There was no "placebo" treatment, and patients in the control group might have produced positive outcomes and reduced the magnitude of differences compared with the intervention group.

Conclusions: Compared with usual care, pharmaceutical care significantly reduced hospitalizations and emergency service consultations by outpatients with BD-I.

Disclosures: This study received funding from the Universidad de Antioquia, Committee for Development Research and Sustainability Program, CODI, (2013-2014 and 2014-2015). Humax Pharmaceutical provided support for the initial development of the EMDADER-TAB trial without commercial interest in the outcomes derived from the trial. Salazar-Ospina reports grants from Credito Beca Francisco José de Caldas Scholarship for Doctoral Programs (528), which also contributed to the support of this study. González-Avendaño is an employee of Humax Pharmaceutical. The other authors have nothing to disclose. Study concept and design were contributed by Benjumea, Faus, and Rodriguez, along with Salazar-Ospina and Amariles. Salazar-Ospina took the lead in data collection, assisted by González-Avendaño, and data interpretation was performed by Salazar-Ospina, Hincapié-García, and González-Avendaño. The manuscript was written primarily by Salazar-Ospina, with assistance from Amariles and González-Avendaño, and revised by all the authors.

PubMed Disclaimer

Conflict of interest statement

This study received funding from the Universidad de Antioquia, Committee for Development Research and Sustainability Program, CODI, (2013-2014 and 2014-2015). Humax Pharmaceutical provided support for the initial development of the EMDADER-TAB trial without commercial interest in the outcomes derived from the trial. Salazar-Ospina reports grants from Credito Beca Francisco José de Caldas Scholarship for Doctoral Programs (528), which also contributed to the support of this study. González-Avendaño is an employee of Humax Pharmaceutical. The other authors have nothing to disclose.

Study concept and design were contributed by Benjumea, Faus, and Rodriguez, along with Salazar-Ospina and Amariles. Salazar-Ospina took the lead in data collection, assisted by González-Avendaño, and data interpretation was performed by Salazar-Ospina, Hincapié-García, and González-Avendaño. The manuscript was written primarily by Salazar-Ospina, with assistance from Amariles and González-Avendaño, and revised by all the authors.

Figures

FIGURE 1
FIGURE 1
The Dader Method
FIGURE 2
FIGURE 2
Patient Flowchart During the EMDADER-TAB Study
FIGURE 3
FIGURE 3
One-year Kaplan-Meier Survival Curves for EMDADER-TAB Patients: Psychiatric Hospitalization and Emergency Service Consultations
FIGURE 4
FIGURE 4
One-year Kaplan-Meier Survival Curves for EMDADER-TAB Patients: Unscheduled Outpatient Visits
See this image and copyright information in PMC

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.
    1. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(Suppl 9):47-51. - PubMed
    1. Brenner CJ, Shyn SI.. Diagnosis and management of bipolar disorder in primary care: a DSM-5 update. Med Clin North Am. 2014;98(5):1025-48. Available at: http://www.medical.theclinics.com/article/S0025-7125(14)00092-3/fulltext. Accessed November 28, 2016. - PubMed
    1. Ministerio de la Protección Social and Fundación FES Social. Estudio Nacional de Salud Mental–Colombia, 2003 [National Mental Health Study–Colombia, 2003]. 2005. Available at: https://www.minsalud.gov.co/Documentos%20y%20Publicaciones/ESTUDIO%20NAC.... Accessed November 28, 2016.
    1. Velligan DI, Weiden PJ, Sajatovic M, et al. .. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1-46. - PubMed

Associated data